BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

...Chicago has leflunomide in a Phase I trial to treat COVID-19, and Immunic AG and Panoptes Pharma GmbH...
BioCentury | Nov 9, 2015
Financial News

Panoptes Pharma completes venture financing

Panoptes Pharma GmbH , Vienna, Austria Business: Ophthalmic Date completed: 2015-11-02 Type: Venture financing Raised: Not disclosed Investors: Aws-Founders Fund; existing investors; and other undisclosed investors Note: The amount raised is not disclosed. WIR Staff Ophthalmic...
BioCentury | Mar 2, 2015
Company News

Panoptes Pharma, Mediolanum Farmaceutici deal

...small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) is in preclinical testing to treat chronic uveitis. Panoptes Pharma GmbH...
BioCentury | Jun 2, 2014
Emerging Company Profile

Panoptes: Dual attack in uveitis

...Xetra:VSC), Martinsried, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland OphthaliX Inc. (OTCBB:OPLI), Carson City, Nev. Panoptes Pharma GmbH...
...Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Servier , Neuilly-sur-Seine, France Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Sidebars Panoptes Pharma GmbH...
BioCentury | Sep 30, 2013
Financial News

Panoptes Pharma completes venture financing

Panoptes Pharma GmbH , Vienna, Austria Business: Ophthalmic Date completed: 9/26/13 Type: Venture financing Raised: €1.2 million ($1.6 million) Investors: aws-Life Science Austria; private investors WIR Staff...
BioCentury | Sep 30, 2013
Company News

4SC, Panoptes Pharma deal

...and royalties. The companies could not be reached for details. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Panoptes Pharma GmbH...
BioCentury | Sep 27, 2013
Financial News

Panoptes closes EUR1.2M seed round, in-licenses 4SC compound

Panoptes Pharma GmbH (Vienna, Austria) raised EUR 1.2 million ($1.6 million) in a seed round from AWS-Life Science Austria and private investors and received rights to preclinical chronic uveitis and conjunctivitis compound PP-001 from 4SC...
Items per page:
1 - 7 of 7
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

...Chicago has leflunomide in a Phase I trial to treat COVID-19, and Immunic AG and Panoptes Pharma GmbH...
BioCentury | Nov 9, 2015
Financial News

Panoptes Pharma completes venture financing

Panoptes Pharma GmbH , Vienna, Austria Business: Ophthalmic Date completed: 2015-11-02 Type: Venture financing Raised: Not disclosed Investors: Aws-Founders Fund; existing investors; and other undisclosed investors Note: The amount raised is not disclosed. WIR Staff Ophthalmic...
BioCentury | Mar 2, 2015
Company News

Panoptes Pharma, Mediolanum Farmaceutici deal

...small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) is in preclinical testing to treat chronic uveitis. Panoptes Pharma GmbH...
BioCentury | Jun 2, 2014
Emerging Company Profile

Panoptes: Dual attack in uveitis

...Xetra:VSC), Martinsried, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland OphthaliX Inc. (OTCBB:OPLI), Carson City, Nev. Panoptes Pharma GmbH...
...Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Servier , Neuilly-sur-Seine, France Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Sidebars Panoptes Pharma GmbH...
BioCentury | Sep 30, 2013
Financial News

Panoptes Pharma completes venture financing

Panoptes Pharma GmbH , Vienna, Austria Business: Ophthalmic Date completed: 9/26/13 Type: Venture financing Raised: €1.2 million ($1.6 million) Investors: aws-Life Science Austria; private investors WIR Staff...
BioCentury | Sep 30, 2013
Company News

4SC, Panoptes Pharma deal

...and royalties. The companies could not be reached for details. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Panoptes Pharma GmbH...
BioCentury | Sep 27, 2013
Financial News

Panoptes closes EUR1.2M seed round, in-licenses 4SC compound

Panoptes Pharma GmbH (Vienna, Austria) raised EUR 1.2 million ($1.6 million) in a seed round from AWS-Life Science Austria and private investors and received rights to preclinical chronic uveitis and conjunctivitis compound PP-001 from 4SC...
Items per page:
1 - 7 of 7